Compare Danaher Corporation (DHR) vs Lucid Group Inc (LCID) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Lucid Group Inc — how do they compare? Danaher Corporation trades at $197.72 (market cap $140.88B), while Lucid Group Inc trades at $4.61 (market cap $1.80B). The key difference: Danaher Corporation is far larger — about 78.3× Lucid Group Inc's market cap, and Danaher Corporation pays a 0.8% dividend while Lucid Group Inc pays none. Which is the better fit depends on your goals.
| DHR | LCID | |
|---|---|---|
Market Cap | $140.88B | $1.80B |
Sector | Health | Consumer Cyclical |
52-Week High | $242.05 | $31.30 |
52-Week Low | $161.91 | $4.62 |
Enterprise Value | $153.66B | $4.27B |
Dividend Yield | 0.8% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $199.05, showing minimal daily change, with a bullish technical signal supported by moving averages. The company maintains strong profitability with a 58.94% gross margin and has beaten earnings estimates for the last three quarters. Recent news highlights the acquisition of Masimo and new product launches in its SCIEX division, indicating growth initiatives. Cash flow improved in 2025 to a net inflow of $2.54 billion, though revenue growth remains modest.
The outlook is positive with a consensus price target of $211.33, representing a 6% upside, and 69% of analysts rate it a buy. Risks include slowing revenue growth, high valuation multiples, and integration challenges from acquisitions. The stock offers a dividend yield supported by stable cash flows, but investors should monitor competitive pressures in the life sciences sector.
Lucid Group (LCID) trades at $5.51, down 0.72% amid significant volatility following bankruptcy rumors that the company denied on July 14, 2026. The stock shows bearish technical signals with negative financial metrics including a -239.81% net income margin and consistent earnings misses. Recent news highlights restructuring advisory engagement and multiple class-action lawsuits filed against the company, creating substantial investor uncertainty.
The outlook remains highly speculative with severe fundamental challenges including massive losses, negative cash flow, and declining revenue. While analyst consensus targets $10.50, representing 91% upside, the overwhelming hold/sell ratings and ongoing legal pressures suggest significant downside risk. Investment requires high risk tolerance given the company's financial distress and competitive EV market pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Lucid Group Inc
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →
